Sarepta Therapeutics stock falls 1.28 percent as DMD data land

Published on 09/30/2026 at 20:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sarepta Therapeutics stock posted Q2 revenue of USD 401.25 million and EPS of USD 0.64 on August 5, 2026. ELEVIDYS data covered older patients at the September 30 congress.

SRPT, US8036071004, Illustration mit AI erstellt.

Sarepta Therapeutics (ISIN US8036071004) was trading at EUR 16.23 at Lang & Schwarz on September 30, 2026 at 8:13 p.m. CEST, down 1.28 percent from the prior close of EUR 16.44. The after-hours quote followed new clinical data on ELEVIDYS presented at the World Muscle Society congress, with findings covering older ambulatory patients with Duchenne muscular dystrophy.

ELEVIDYS data reach older patients

According to GuruFocus on September 30, 2026, Sarepta presented data showing sustained functional improvements in ambulatory patients who were 8 to 12 years old at treatment. The comparison covered two years against a well-matched control group, extending the clinical discussion beyond younger patients.

The same update described a separate analysis of children aged 2 to 3 years. Twelve weeks after treatment, the analysis showed dystrophin expression and correct localization in muscle tissue, while nausea and vomiting were identified as the most common side effects in the reported safety profile.

Revenue beat estimates but declined

According to MarketBeat, Sarepta reported Q2 2026 revenue of USD 401.25 million and quarterly EPS of USD 0.64. Revenue exceeded the USD 366.39 million consensus estimate, while EPS surpassed the USD 0.22 estimate, but revenue was down 34.3 percent from the prior-year quarter.

The figures create a mixed operating picture: the earnings comparison was positive, while the year-over-year sales comparison remained negative. The September data therefore matter because the commercial value of ELEVIDYS depends on whether clinical evidence can support demand across a wider patient population.

Safety remains a key constraint

A StockTitan release dated September 25, 2026 states that the ELEVIDYS label carries a boxed warning for acute serious liver injury and acute liver failure. That risk remains an important counterweight to the broader age-related efficacy findings and keeps regulatory and safety execution central to the stock story.

Sarepta stock trades lower after data

Sarepta Therapeutics stock was trading at EUR 16.23 at Lang & Schwarz on September 30, 2026 at 8:13 p.m. CEST, down 1.28 percent versus the Lang & Schwarz prior close of EUR 16.44. The company had a market capitalization of USD 1.9 billion and a 52-week range of USD 14.68 to USD 25.32 as of September 30, 2026.